Analysis of ischemia/reperfusion injury in time‐zero biopsies predicts liver allograft outcomes

Jason M. Ali, Susan E. Davies, Rebecca J. Brais, Lucy V. Randle, John R. Klinck, Michael E. D. Allison, Yining Chen, Laura Pasea, Simon F. J. Harper, Gavin J. Pettigrew – 26 December 2014 – Ischemia/reperfusion injury (IRI) that develops after liver implantation may prejudice long‐term graft survival, but it remains poorly understood. Here we correlate the severity of IRIs that were determined by histological grading of time‐zero biopsies sampled after graft revascularization with patient and graft outcomes.

Thrombolytic protocol minimizes ischemic‐type biliary complications in liver transplantation from donation after circulatory death donors

John B. Seal, Humberto Bohorquez, Trevor Reichman, Adam Kressel, Anand Ghanekar, Ari Cohen, Ian D. McGilvray, Mark S. Cattral, David Bruce, Paul Greig, Ian Carmody, David Grant, Markus Selzner, George Loss – 26 December 2014 – Liver transplantation (LT) with donation after circulatory death (DCD) donors has been associated with a high rate of ischemic‐type biliary strictures (ITBSs) and inferior graft survival.

Recombinant adeno‐associated virus–mediated inhibition of microRNA‐21 protects mice against the lethal schistosome infection by repressing both IL‐13 and transforming growth factor beta 1 pathways

Xing He, Jun Xie, Dongmei Zhang, Qin Su, Xue Sai, Ruipu Bai, Chao Chen, Xufeng Luo, Guangping Gao, Weiqing Pan – 24 December 2014 – Schistosomiasis is a serious parasitic disease in humans, which can lead to liver fibrosis and death. Accumulating evidence indicated that targeting the deregulated microRNAs (miRNAs) could mitigate disease outcomes.

Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus–coinfected patients with mild fibrosis in the short term

Juan Macías, María Mancebo, Manuel Márquez, Dolores Merino, Francisco Téllez, Antonio Rivero, Miguel A. von Wichmann, Luis F. López‐Cortés, Nicolás Merchante, Jesús Santos, Miguel Raffo, Montserrat Pérez‐Pérez, Ángela Camacho, Jose A. Iribarren, Juan A. Pineda – 24 December 2014 – Liver fibrosis is used to make decisions about the timing of therapy against hepatitis C virus (HCV) in routine clinical practice, which should be based on the short‐term likelihood of liver decompensations.

Farnesoid X receptor–induced lysine‐specific histone demethylase reduces hepatic bile acid levels and protects the liver against bile acid toxicity

Young‐Chae Kim, Sungsoon Fang, Sangwon Byun, Sunmi Seok, Byron Kemper, Jongsook Kim Kemper – 24 December 2014 – Bile acids (BAs) function as endocrine signaling molecules that activate multiple nuclear and membrane receptor signaling pathways to control fed‐state metabolism. Since the detergent‐like property of BAs causes liver damage at high concentrations, hepatic BA levels must be tightly regulated.

Subscribe to